Costs of treatment of chronic obstructive pulmonary disease

Advances in Experimental Medicine and Biology

Volumn 885, Issue , 2016, Pages 67-75

  Milewska, A ^a   Rysiak, E ^b   Zareba, I ^b   Holownia, A ^b   Mroz, R M ^a,b  

^a Respiratory Medicine Center   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

COPD; Direct costs; Exacerbations; Medical costs; Pharmacoeconomics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BUDESONIDE; CLARITHROMYCIN; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DYSPNEA; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ECONOMICS; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; FORCED EXPIRATORY VOLUME; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84964409614     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/5584_2015_199     Document Type: Chapter

References (24)

1. Ayres JG, Price MJ, Efthimiou J (2003) Costeffectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double blind randomized, placebo controlled trial. Respir Med 97:212-220
2. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694
3. Caramori G, Adcock IM, Papi A (2009) Clinical definition of COPD exacerbations and classification of their severity. South Med J 102:277-282
4. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178:332-338
5. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring EJ, She D (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 1:63-70
6. Doherty DE, Belfer MH, Brunton SA, Fromer L, Morris CM, Snader TC (2006) Chronic obstructive pulmonary disease: consensus recommendations for early diagnosis and treatment. J Fam Pract 55(Suppl 1):51-58
7. D’Souza AO, Smith MJ, Miller LA, Kavookjian J (2006) An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 129:1693-1708
8. GOLD (2011) From the global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease. Available from: http://www.goldcopd.org. Accessed 15 Sept 2014
9. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM (2006) Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28:523-532
10. Hilleman DE, Dewan N, Malesker M, Friedman M (2000) Pharmacoeconomic evaluation of COPD. Chest 118:1278-1285
11. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128-1138
12. Jahnz-Rożyk K, Targowski T, From S (2011a) Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007-results of multicenter Polish study. Pol Merkur Lekarski 26:208-214
13. Jahnz-Rożyk K, Targowski T, From S, Faluta T, Borowiec L (2011b) Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland. Pneumonol Alergol Pol 79:337-342
14. Jemal A, Ward E, Hao Y, Thun M (2005) Trends in the loading causes of heath in the United States 1970-2002. JAMA 294:1255-1259
15. Kopec JA, Willison KD (2003) A comparative review of four preferencje weighted measures of health related quality of life. J Clin Epidemiol 56:317-325
16. Mannino DM (2003) Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 48 (1185):1191
17. Mapel DW, Roberts MH (2012) New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics 30:869-885
18. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Löfdahl CG (2004) COPD exacerbations: the importance of a standard definition. Respir Med 98:99-107
19. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J (2005) Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60:992-997
20. Starkie HJ, Briggs AH, Chambers MG (2008) Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 3:71-88
21. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543-1554
22. Vázquez-Polo FJ, Moreno E, Negrín MA, Giron FJ, Martínez ML (2011) Comparing meta-analyses for chronic obstructive pulmonary disease. Expert Rev Pharmacoecon Outcomes Res 11:277-279
23. WHO (2011) World Health Statistics 2011. Available from: http://www.who.int/entity/whosis/whostat/EN_WHS2011_Full.pdf. Accessed 10 Sept 2014
24. Wouters EF (2003) Economic analysis of the confronting COPD survey: an overview of results. Respir Med 97:3-14